vTv Therapeutics to host virtual KOL event on hypoglycemia in type 1 diabetes, cadisegliatin Phase 3 program
VTVT•vTv Therapeutics will host a virtual event on hypoglycemia in type 1 diabetes on Oct. 20, 2026, with discussion of cadisegliatin’s Phase 3 CATT1 program; topline trial data are expected in mid-2027.
1. Virtual event
The event begins at 2:30 p.m. ET on Oct. 20, 2026. External experts and company management will discuss hypoglycemia in type 1 diabetes and cadisegliatin’s Phase 3 CATT1 program.
2. Trial timing
Topline data from the CATT1 trial are expected in mid-2027.
